Indeed, treatment of patients with multiple sclerosis (MS) with Atacicept (TACI-Ig), an antagonist of BAFF and APRIL, led to an unexpected increase in inflammatory activity and condemned the Atacicept trials in MS[136]. The gene discussed is TNFSF13; the disease is myeloid sarcoma.